CVS Health vs UnitedHealth CVS vs UNH
CVS Health and UnitedHealth on one sheet: valuation multiples, growth, margins, debt, dividends and returns, each section labelled with the period it covers, from the companies' filings. Add or remove a stock above the sheet; the link holds the set.
What differs most
- Market value: UnitedHealth $360.32B, CVS Health $118.13B.
- Price / sales: UnitedHealth 0.8×, CVS Health 0.3×.
- Net margin: UnitedHealth 3.1%, CVS Health 1.2%.
- Operating margin: UnitedHealth 4.8%, CVS Health 2.0%.
Price return
2025-10-16 → 2026-10-16
CVS+13.5%
UNH+12.5%
Profile
latestSector
Healthcare
Healthcare
Industry
Medical - Healthcare Plans
Medical - Healthcare Plans
Market value
$118.13B
$360.32B
Enterprise value
$168.21B
$405.06B
Employees
259,500
390,000
Revenue per employee (TTM)
$1.6M
$1.2M
Our models
nightlythe valuation on each stock's pagePrice vs model
420% overvalued vs model
19% overvalued vs model
Model range
$17.75–108
$198–886
Models in the headline
1
1
FCF growth priced in, at a 10% return
11.5%
14.1%
Every model, its assumptions and its range: CVS valuation · UNH valuation. The growth priced in, at any return: CVS reverse DCF · UNH reverse DCF.
Trading
close 2026-10-16Last close
$92.36
$401.43
52-week high
$110.60
$436.35
52-week low
$70.08
$259.02
Price vs 52-week high
−16.5%
−8.0%
Price vs 52-week low
+31.8%
+55.0%
Average daily volume / shares
0.6%
0.6%
Beta
0.60
0.61
Returns
to 2026-10-161 month
+0.7%
+7.0%
3 months
−13.3%
−5.2%
6 months
+20.3%
+26.9%
Year to date
+16.4%
+21.6%
1 year
+13.5%
+12.5%
1 year, dividends added
+16.8%
+15.1%
2 years
+42.0%
−29.7%
Valuation
price × TTM to Jun 2026P/E (TTM)
24.4×
25.8×
P/E on consensus EPS (next FY)
11.5×
19.8×
Price / sales
0.3×
0.8×
EV / sales
0.4×
0.9×
EV / EBITDA
13.1×
15.6×
Price / book
1.5×
—
Price / free cash flow (FY)
15.1×
22.4×
Free-cash-flow yield (FY)
6.6%
4.5%
Growth
TTM and FY2025Revenue growth (TTM)
—
—
Revenue growth, consensus next FY
+3.6%
+0.1%
Revenue, 3-year CAGR
7.6%
11.4%
Revenue, 5-year CAGR
8.4%
11.7%
EPS growth (TTM)
—
—
EPS growth, consensus next FY
+477.2%
+53.5%
EPS, 3-year CAGR
−23.8%
−14.5%
Free cash flow, 3-year CAGR
−16.6%
−11.8%
Diluted shares, 3-year change
−3.9%
−4.1%
Profitability
TTM to Jun 2026Gross margin (FY)†
13.8%
18.5%
Operating margin
2.0%
4.8%
EBITDA margin
3.1%
5.8%
Net margin
1.2%
3.1%
Free-cash-flow margin (FY)
1.9%
3.6%
Return on equity
6.1%
—
Return on assets
1.9%
4.6%
Asset turnover
1.64
1.45
† Gross margin (FY): As filed. Companies draw the cost-of-revenue line in different places, so gross margins of two companies in one industry can differ for that reason alone; operating margin does not depend on where the line is drawn.
Balance sheet
MRQ Jun 2026Cash
$11.33B
$28.59B
Total debt
$61.41B
$73.33B
Net debt
$50.08B
$44.74B
Debt / equity
0.8×
—
Net debt / EBITDA (TTM)
3.9×
1.7×
Interest coverage (FY)
3.3×
4.7×
Current ratio (FY)
0.84
0.79
Dividends
trailing 12 monthsDividend yield
2.9%
2.3%
Dividends per share
$2.66
$9.06
Payout ratio (of TTM EPS)
70.2%
58.2%
Dividend per share, 5-year CAGR
5.9%
10.9%
Frequency
Quarterly
Quarterly
Ownership and activity
last 90 days · latest 13FTracked superinvestors holding (13F)
12
20
Insider open-market buys (Form 4)
$0
$0
Insider sales (Form 4)
$0
$661K
Analyst upgrades
0
0
Analyst downgrades
0
0
Statements
income TTM to Jun 2026 · cash flow FY2025Revenue
$415.09B
$450.13B
EBITDA
$12.81B
$25.96B
Operating income
$8.29B
$21.68B
Net income
$4.89B
$14.12B
EPS (diluted)
$3.79
$15.58
Operating cash flow
$10.64B
$19.70B
Capital expenditure
−$2.83B
−$3.62B
Free cash flow
$7.81B
$16.07B
Dividends paid
$3.40B
$7.92B
Statements from the companies' SEC filings; prices, dividends and consensus estimates from Financial Modeling Prep; insider trades from Form 4 and holdings from 13F. Refreshed nightly. A comparison of filed numbers, not a recommendation to buy, sell or hold any security.